EA
PRCT icon

Enclave Advisors’s Procept Biorobotics PRCT Stock Holding History

Enclave Advisors’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$656K Hold
29,068
– – 0.08% 85
2026
Q1 		$727K Hold
29,068
– – 0.1% 82
2025
Q4 		$914K Hold
29,068
– – 0.13% 74
2025
Q3 		$1.04M Hold
29,068
– – 0.16% 60
2025
Q2 		$1.67M Hold
29,068
– – 0.27% 48
2025
Q1 		$1.69M Sell
29,068
-500
-2% -$34.1K 0.29% 47
2024
Q4 		$2.38M Buy
29,568
+1,499
+5% +$128K 0.39% 42
2024
Q3 		$2.25M Buy
+28,069
New +$1.99M 0.38% 40

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Enclave Advisors's PRCT Position: Q2 2026 in Review

Enclave Advisors held its Procept Biorobotics (PRCT) position steady in Q2 2026 at 29,068 shares worth $656K. The position accounts for 0.08% of the portfolio, ranked #85.

Enclave Advisors first reported a position in PRCT in Q3 2024 and has held it in 8 quarters since. The position peaked at $2.38M in Q4 2024. 254 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

  • Enclave Advisors held 29,068 shares of Procept Biorobotics worth $656K as of Q2 2026.
  • Enclave Advisors left its Procept Biorobotics share count unchanged in Q2 2026.
  • Procept Biorobotics made up 0.08% of Enclave Advisors's portfolio in Q2 2026, its #85 holding.
  • Enclave Advisors first reported a position in Procept Biorobotics in Q3 2024 and has held it in 8 quarters since.
  • Enclave Advisors's Procept Biorobotics position peaked at $2.38M in Q4 2024.
  • 254 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on Enclave Advisors's 13F filing for Q2 2026, filed 14 Jul 2026.